Citigroup’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

Citigroup’s Portfolio AXN Stock Details AXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-807	Closed	-$1K	–	8014
2015 Q4	$1K	Hold	807	–	–	﹤0.01%	7472
2015 Q3	$1K	Buy	+807	New	+$1.27K	﹤0.01%	7288

Other funds holding AXN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

MUFG Americas New York $4.04B AUM 12.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's AXN Position: Q1 2016 in Review

Citigroup sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q1 2016, closing a stake of 807 shares — an estimated $1K sold.

Citigroup first reported a position in AXN in Q3 2015 and held it in 2 quarters. The position peaked at $1K in Q4 2015. 11 funds tracked by Wall St. Rank hold AXN as of Q1 2016.

Citigroup reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q1 2016 after selling out during the quarter.
Citigroup sold 807 Aoxing Pharmaceutical Company Inc. shares in Q1 2016, an estimated $1K.
Citigroup first reported a position in Aoxing Pharmaceutical Company Inc. in Q3 2015 and held it in 2 quarters.
Citigroup's Aoxing Pharmaceutical Company Inc. position peaked at $1K in Q4 2015.
11 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q1 2016.

Based on Citigroup's 13F filing for Q1 2016, filed 13 May 2016.